BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lubris, Biomodels, LLC Report on Potential New Therapy for Osteoarthritis


10/20/2009 10:45:57 AM

PHILADELPHIA, Oct. 19 /PRNewswire/ -- Medical researchers will report findings today (Oct. 19) that demonstrate that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration.

The discovery by scientists at Biomodels, a preclinical drug research organization, and Lubris, a Massachusetts-based startup company, could result in a new therapy for individuals at risk for osteoarthritis, researchers said.

The study, by Gregory D. Jay, MD, PhD, a Professor of Emergency Medicine and Biomedical Engineering at Rhode Island Hospital and Brown University, will be presented Monday morning at the American College of Rheumatology/Association of Rheumatology Health Professionals Conference.

In the study performed at Biomodels, the transection of the ACL (anterior cruciate ligament) in untreated rats resulted in progressive degeneration of the knee joints and the articular cartilage. In rats treated with recombinant human lubricin, however, the degeneration was far less pronounced, indicating that treatment with lubricin can slow the development of osteoarthritis following traumatic joint injury, and possibly reverse the process, according to Dr. Jay.

Dr. Jay said the study shows that recombinant human lubricin, given as direct injections, "significantly reduced the extent of cartilage degeneration in the knees of rats with post-traumatic osteoarthritis."

"If the research can be successfully translated into humans, it would represent the first successful attempt to protect cartilage and improve boundary lubrication in compromised joints, which could revolutionize both the treatment of osteoarthritis and traumatic joint injury," he said

Dr. Jay's ongoing research suggests that lubricin injections could delay or even prevent the onset of osteoarthritis and reduce or eliminate the need for costly joint-replacement surgery.

The findings are supportive of more than two decades of research by Dr. Jay and his team, in which they have shown that lubricin is a key component of human synovial fluid, itself a requirement for the normal function and lubrication of healthy joints.

Abstract:

http://acr.confex.com/acr/2009/webprogram/Paper13868.html

About Lubris LLC

Lubris, a Massachusetts-based startup company, is developing lubricin commercially and holds exclusive worldwide patent rights to make, use, and sell lubricin. The company is in the process of accessing capital markets to develop and commercialize lubricin-containing products in various orthopedic and other indications.

About Biomodels LLC

Biomodels (www.biomodels.com), a preclinical drug research organization founded in 1997, develops and conducts predictive translational studies for biotechnology and pharmaceutical companies, particularly in the areas of cancer, cancer supportive care, radiation therapy, and inflammatory diseases.

The company, based in Watertown, MA, specializes in (non-GLP) efficacy studies that optimize dose, schedule and define mechanism of action. The company also has expertise in modeling inflammatory diseases, including those conditions affecting the gastrointestinal tract. Biomodels' studies enable organizations to more readily identify lead compounds, decrease the time to a clinical trial and increase the chance of clinical success.

SOURCE Biomodels

CONTACT: Barry Wanger, Media Relations/Lubris, Wanger Associates,
Barry@WangerAssociates.com, +1-617-965-6469

Web site: http://www.biomodels.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES